Songhui Zhao

Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma

Jianzhen Lin, Xu Yang, Junyu Long et al. · HepatoBiliary Surgery and Nutrition · 2020 · 155 citations · Full text

Medicine, Oncology, Pharmacology +12

Integration of comprehensive genomic profiling, tumor mutational burden, and PD‐L1 expression to identify novel biomarkers of immunotherapy in non‐small cell lung cancer

Yunfei Shi, Youming Lei, Li Liu et al. · Cancer Medicine · 2021 · 115 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients

Jingyu Cao, Jing Hu, Siqin Liu et al. · JCO Precision Oncology · 2020 · 93 citations · Full text

Medicine, Genetics, Oncology +17

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in <i>HER2</i>-Mutant Lung Adenocarcinoma

Wenfeng Fang, Shen Zhao, Ying Liang et al. · The Oncologist · 2019 · 66 citations · Full text

Medicine, Oncology, Pharmacology +17

<i>NFE2L2/KEAP1</i> Mutations Correlate with Higher Tumor Mutational Burden Value/PD-L1 Expression and Potentiate Improved Clinical Outcome with Immunotherapy

Xian Xu, Yang Yang, Xiaoyan Liu et al. · The Oncologist · 2020 · 58 citations · Full text

Medicine, Cancer Biology, Oncology +17